
👁️Ozempic and Zepbound Eye Risk Warnings: What to Watch For
Ozempic and Zepbound now carry rare but serious eye-risk warnings. Learn the NAION symptoms, what the evidence shows, and when to seek urgent care.
Scanura Editorial
Health Education Team
Written by Scanura Editorial for health education. This article is not a substitute for advice from a qualified doctor. About our editorial standards
Ozempic and Zepbound Eye Risk Warnings: What to Watch For
A sudden change in vision after starting a weight-loss or diabetes injection can be frightening. You may have seen headlines linking Ozempic, Zepbound and a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). You may also have heard that these injections can cause glaucoma or worsen diabetic retinopathy.
The direct answer: On November 9, 2026, the US FDA required all GLP-1 receptor agonist medicines—including Ozempic and Zepbound—to add a warning about a potential increased risk of rare NAION. NAION can cause sudden, painless loss of vision in one eye and sometimes permanent damage. FDA said the evidence supports a potential increased risk, not proof that every case was caused by the medicine.
In brief: New vision symptoms while taking Ozempic or Zepbound should not be dismissed or treated as a normal side effect. Sudden painless vision loss, a blind spot, tunnel vision, distorted colours or new central blur needs prompt medical assessment. Do not wait for a routine appointment, and do not independently stop or change other diabetes medicines.
What Changed in the Ozempic and Zepbound Eye Warnings?
FDA’s November 2026 safety communication applies to the GLP-1 receptor agonist class. Its list includes semaglutide medicines such as Ozempic, Rybelsus and Wegovy, and tirzepatide medicines such as Mounjaro and Zepbound.
The agency is requiring application holders to add NAION information to the Warnings and Precautions section of the product labelling. Its conclusions came from a review of clinical trials, post-marketing reports, observational studies, published literature and animal data.
This wording matters. FDA concluded that there is a potential increased risk of rare NAION events, while noting important limitations: GLP-1 users often already have conditions that also raise NAION risk; adverse-event reports cannot establish causation; individual trials had too few events, so FDA pooled 126 trials; and its animal review found no explanatory mechanism.
The warning is not a reason to panic or assume vision loss is inevitable. It is a reason to know the symptoms and seek care quickly.
Labels vary by country: EMA classified NAION as a very rare semaglutide side effect in June 2025, while local approvals and labels in India and elsewhere may differ. Follow your prescriber and local insert.
Which Eye Problems Are Being Discussed?
| Eye event | What it means | Typical warning signs | What to do |
|---|---|---|---|
| NAION | Reduced blood flow damages the front of the optic nerve; it is not the same as a blocked retinal artery | Sudden painless loss of vision in one eye, blind spot or tunnel vision, distorted colours, reduced central sharpness | Contact a healthcare professional right away; sudden marked loss needs emergency assessment |
| Diabetic retinopathy complications | Damage to retinal blood vessels may appear to worsen when glucose improves rapidly | New blur, floaters, dark spots or missing areas of vision in someone with diabetes | Contact the diabetes/eye-care team promptly; do not assume the injection is the only cause |
| Other eye emergencies | Acute angle-closure glaucoma, retinal detachment, stroke and other conditions can also cause sudden visual change | Painful red eye with halos, a curtain or shadow over vision, weakness, speech difficulty or other neurological symptoms | Seek emergency care; these are not diagnoses an article can make |
“Eye risk” is a broad phrase used in media and social posts. The November 2026 FDA action specifically concerns NAION. Diabetic retinopathy is a separate, established warning in the Ozempic and Zepbound labels.
What Is NAION?
Non-arteritic anterior ischemic optic neuropathy affects the optic nerve, the cable that carries visual information from the eye to the brain. “Non-arteritic” means the problem is not caused by inflammation of the artery wall.
The American Academy of Ophthalmology describes NAION as sudden loss of vision caused by damage to the optic nerve from poor blood flow. Vision loss is usually painless and affects one eye first. The disc at the front of the optic nerve becomes swollen, and the damaged nerve fibres may not recover fully.
NAION is different from cataract, diabetic retinopathy and central retinal artery occlusion. Only an eye specialist can determine which condition is present. The warning is meant to trigger fast assessment—not to encourage self-diagnosis.
NAION Warning Signs: When to Seek Help Immediately
FDA lists the following symptoms of NAION:
- Sudden, painless vision loss in one eye, sometimes noticed when waking up;
- Blurred or missing portions of vision, including blind spots or tunnel vision;
- Distortion of colours; and
- Reduced central sharpness, such as new blurred or hazy spots.
Do not wait for the next weekly injection, a routine eye test or a regular diabetes appointment. FDA advises patients to contact their healthcare professional right away if these symptoms occur and says clinicians should promptly refer a suspected case to an ophthalmologist.
Sudden severe or obvious vision loss, a curtain over the eye, weakness, trouble speaking or a sudden painful red eye with halos require emergency care. These findings may point to a different emergency, including acute angle-closure glaucoma or stroke. Do not drive yourself if your vision is unsafe.
A history of NAION in one eye increases the chance of recurrence in the other. Anyone with previous NAION should tell their prescribing clinician and eye specialist before treatment.
How Rare Is the Risk, and What Does the Evidence Show?
FDA’s Clinical-Trial Review
FDA pooled 126 randomised controlled trials involving 134,253 participants: 78,217 received a GLP-1 medicine and 56,036 received a placebo or another glucose-lowering medicine. Across 288,879 person-years of follow-up, FDA identified 15 probable NAION events—10 in GLP-1 users and five in comparator groups.
The observed incidence was:
- 6.4 NAION events per 100,000 person-years with GLP-1 medicines; and
- 3.8 events per 100,000 person-years with placebo or a non-GLP-1 comparator.
For context, FDA cited a general-population incidence of 2.3 to 10.2 NAION events per 100,000 people per year in adults over 50. NAION is therefore rare, but the outcome can be serious.
FDA’s Real-World Sentinel Review
Among adults with type 2 diabetes who started a GLP-1 medicine or another diabetes medicine between 2019 and 2024, incidence ranged from 26 to 32 events per 100,000 person-years. Compared with SGLT2 inhibitors, GLP-1 use was not associated with a statistically significant increase: hazard ratio 1.19, 95% confidence interval 0.91–1.54. Compared with DPP-4 inhibitors, there was an increased risk: hazard ratio 1.43, 95% CI 1.02–2.01.
The Semaglutide Observational Study
A 2024 JAMA Ophthalmology study used records from 16,827 neuro-ophthalmology patients without previous NAION. In matched groups with type 2 diabetes, 36-month cumulative incidence was 8.9% with prescribed semaglutide versus 1.8% with a non-GLP-1 diabetes medicine; the adjusted hazard ratio was 4.28 (95% CI 1.62–11.29). In a matched overweight or obesity group, incidence was 6.7% versus 0.8%, with a hazard ratio of 7.64 (95% CI 2.21–26.36).
Those figures must not be applied directly to every Ozempic user. The study was retrospective, used prescription records, selected neuro-ophthalmology patients and found an association rather than proof of cause. The authors called for further research.
The practical interpretation: NAION remains uncommon, but the risk is not zero and vision can be permanently affected. Rapid recognition matters more than estimating personal risk from a headline.
Why Did EMA Say “Very Rare” for Semaglutide?
EMA’s June 2025 review classified NAION as a very rare side effect of semaglutide—up to 1 in 10,000 users. EMA estimated about one additional case per 10,000 person-years of treatment in adults with type 2 diabetes, and said confirmed NAION should end semaglutide treatment.
For Zepbound, FDA’s newer action is class-wide. That does not mean every product has the same frequency estimate or evidence strength; it means the potential-risk signal is being communicated across the class.
What About the Diabetic Retinopathy Warning?
This is a different issue from NAION, but it is also important.
The current Ozempic label reports data from a two-year trial in people with type 2 diabetes and high cardiovascular risk:
- Diabetic-retinopathy complications occurred in 3.0% of Ozempic users versus 1.8% of placebo users overall.
- Among people who already had diabetic retinopathy, events occurred in 8.2% versus 5.2%.
- Among those without known retinopathy, events occurred in 0.7% versus 0.4%.
The label explains that rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. People with a history of diabetic retinopathy should be monitored for progression.
The Zepbound label also warns that rapid improvement in glucose control may be associated with temporary worsening of retinopathy and advises monitoring people with a history of the condition.
This does not mean Ozempic or Zepbound is bad for the eyes overall. Good long-term glucose control protects the retina and other organs. The problem is that a fast change—particularly at the start or during dose escalation—can expose or temporarily worsen existing retinal disease in some people. A recent eye examination and a plan for monitoring are more useful than abandoning effective diabetes treatment without medical advice.
What Should You Do If Vision Changes?
- Treat sudden visual change as urgent. Contact a healthcare professional right away for the symptoms listed above. Severe loss of vision needs emergency assessment.
- Bring the exact medicine information. Note the generic name, dose, last injection, other diabetes medicines, eye history and when the symptoms began.
- Do not assume screen time, a cold or a new spectacle prescription explains it without an eye assessment.
- Ask for prompt ophthalmology review, as FDA advises for suspected NAION.
- Get a medication decision quickly. FDA says patients who have had NAION should discuss with their clinician whether to continue or stop the GLP-1 medicine. For confirmed NAION, EMA says semaglutide should be stopped. Do not turn a general warning into a personal prescription decision.
- Do not stop insulin or another glucose-lowering medicine on your own. If a GLP-1 medicine is paused, the team may need to adjust the regimen.
- Report the event. The prescriber can document it and use the appropriate local pharmacovigilance system.
A Practical Checklist During Treatment
- Before or soon after starting: tell the prescriber about previous NAION, glaucoma, diabetic retinopathy, macular oedema, prior retinal problems and recent eye surgery. Ask whether an eye assessment is needed before treatment or dose escalation.
- Keep eye appointments: if you have diabetes, retinopathy or other eye disease, follow the screening and review schedule set by your clinician. Do not postpone because weight or HbA1c is improving.
- Track the medicine and dose: a clear record helps clinicians judge the timing of a symptom. Include the last injection date and any dose change.
- Control other risks: attend to blood pressure, diabetes, sleep apnoea, anaemia, kidney health and smoking. These are clinically relevant for NAION and cardiovascular health, although improving them does not prove that a GLP-1 medicine caused an eye event.
- Ask before pregnancy: GLP-1 medicines have pregnancy restrictions; if pregnancy is possible or planned, discuss it promptly rather than continuing treatment without review.
- Remember other contraindications: Ozempic and Zepbound are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. This is separate from the eye warning but remains important.
Frequently Asked Questions
Is Ozempic or Zepbound known to cause blindness?
Neither can be described simply as a blindness-causing drug. The FDA warning concerns a potential increased risk of rare NAION, which can cause permanent vision loss. Most people will never develop it, and an association or warning does not prove that a particular person’s vision loss was caused by the medicine.
Does this warning apply to Wegovy and Mounjaro too?
Yes. FDA’s November 2026 action applies to the GLP-1 receptor agonist class and lists semaglutide and tirzepatide medicines, including Ozempic, Zepbound, Wegovy and Mounjaro. Different labels can still contain product-specific frequency estimates and advice.
Should I stop Ozempic or Zepbound if my vision becomes blurry?
Do not make that change alone unless a clinician has advised it. Seek prompt assessment, especially for sudden painless loss or one-eye symptoms. FDA advises a clinician-led continuation-versus-stopping decision after NAION; EMA advises stopping semaglutide when NAION is confirmed. Never stop insulin or other diabetes treatment without instructions.
Does rapid weight loss or a low HbA1c prove the drug damaged the optic nerve?
No. No proven mechanism has been established, and rapid weight loss, blood-pressure changes and improved glycaemia are hypotheses rather than established explanations. Retinal worsening can occur when glucose control improves rapidly, especially in someone with pre-existing retinopathy. Ask an eye specialist and diabetes clinician to interpret the pattern.
Key Takeaways
- FDA issued a class-wide warning on November 9, 2026. Ozempic and Zepbound labelling must include a potential increased risk of rare NAION.
- NAION is uncommon but high consequence. It can cause sudden, painless vision loss in one eye and sometimes permanent visual damage.
- The warning means potential risk, not proven cause in every patient. Shared risk factors and observational-study limitations make individual causation difficult.
- Know the symptoms. Sudden painless loss, a blind spot or tunnel vision, distorted colours or reduced central sharpness needs prompt medical advice.
- Sudden severe loss is an emergency. Do not wait for the next injection or a routine eye appointment.
- Diabetic retinopathy is a separate warning. Rapid improvement in glucose control can temporarily worsen existing retinopathy, so eye monitoring matters.
- Do not self-adjust diabetes treatment. Get urgent clinical advice about the GLP-1 medicine and any replacement diabetes regimen.
- Existing NAION and other eye risks deserve discussion before treatment. Bring your eye history, medicine list and dose record to the prescriber.
Sources and Further Reading
- U.S. Food and Drug Administration, “FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition”, November 9, 2026.
- U.S. Food and Drug Administration, Ozempic prescribing information, revised June 2026.
- U.S. Food and Drug Administration, Zepbound prescribing information, revised February 2026.
- European Medicines Agency PRAC, “PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy”, June 6, 2025.
- Hathaway JT, Shah MP, Hathaway DB, et al., “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide”, JAMA Ophthalmology, 2024;142(8):732–739.
- American Academy of Ophthalmology, “What Is Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)?”.
- American Academy of Ophthalmology, “What Is Diabetic Retinopathy?”.
Disclaimer: This article is for educational purposes only. It is not medical advice and does not establish a doctor–patient relationship. FDA and EMA warnings may not yet be reflected in every country’s product label. Seek urgent medical care for sudden vision loss or other red-flag symptoms, and consult the prescribing clinician before changing Ozempic, Zepbound, insulin or any other treatment.
Medical References
- FDA — GLP-1 Receptor Agonists: Potential Increased Risk of NAION
- FDA — Ozempic Prescribing Information, 2026
- FDA — Zepbound Prescribing Information, 2026
- EMA PRAC — NAION Is a Very Rare Side Effect of Semaglutide Medicines
- Hathaway JT et al. — NAION Risk in Patients Prescribed Semaglutide, JAMA Ophthalmology
- American Academy of Ophthalmology — What Is NAION?
- American Academy of Ophthalmology — What Is Diabetic Retinopathy?
Step-by-Step Guide
- 1
Recognise the urgent eye symptoms
Sudden painless vision loss in one eye, a blind spot or tunnel vision, distorted colours, or new blurred central vision needs prompt medical advice.
- 2
Get a same-day eye assessment
Contact a healthcare professional right away and ask for prompt ophthalmology review; sudden marked vision loss warrants emergency care.
- 3
Review the medicine with the prescriber
Bring the exact medicine name, dose, last injection date, diabetes status and eye-history to the review rather than changing treatment yourself.
- 4
Discuss whether to continue the GLP-1 medicine
If NAION is suspected, FDA advises a prompt benefit-versus-risk decision; patients should not keep taking or stop a prescription without clinical advice.
- 5
Keep diabetic eye monitoring up to date
People with pre-existing diabetic retinopathy need eye monitoring during GLP-1 treatment, especially while the dose is being increased.
📬 One health report guide, every week
Normal ranges, what your values mean, and what to ask your doctor — in plain language. Free, unsubscribe anytime.